Edoxaban for the prevention of thromboembolic events after surgery

Drugs of Today

Volumn 47, Issue 10, 2011, Pages 753-761

  Gras, Jordi ^a  

^a C/Roger de Flor 3   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIVITAMIN K; ATORVASTATIN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; COUMARIN DERIVATIVE; DALTEPARIN; DIGOXIN; EDOXABAN; ENOXAPARIN; LIXIANA; LOW MOLECULAR WEIGHT HEPARIN; MOXIFLOXACIN; PLACEBO; QUINIDINE; UNCLASSIFIED DRUG; VERAPAMIL; XIMELAGATRAN;

ARTICLE; DRUG SAFETY; HIP FRACTURE; HUMAN; JAPAN; LEG THROMBOSIS; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE THROMBOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; UNSPECIFIED SIDE EFFECT;

ANIMALS; CLINICAL TRIALS AS TOPIC; FACTOR XA; HUMANS; POSTOPERATIVE COMPLICATIONS; PYRIDINES; THIAZOLES; THROMBOEMBOLISM;

EID: 81255211415     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2011.47.10.1709241     Document Type: Article

References (46)

1. th Ed). Chest 2008, 133(6, Suppl.) : 381-453S.
2. Geerts, W.H., Heit, J.A., Clagett, G.P., Pineo, G.F., Colwell, C.W., Anderson, F.A., Wheeler, H.B. Prevention of venous thromboembolism. Chest 2001, 119(1, Suppl.): 132-75S.
3. Nicolaides, A.N., Kakkar, V.V., Field, E.S., Renney, J.T.G. The origin of deep vein thrombosis: A venographic study. Br J Radiol 1971, 44(525): 653-63.
4. Kearon, C. Natural history of venous thromboembolism. Circulation 2003, 107(23, Suppl. 1): I-22-30.
5. Fraser, D.G.W., Moody, A.R., Morgan, P.S., Martel, A.L., Davidson, I. Diagnosis of lower-limb deep venous thrombosis: A prospective blinded study of magnetic resonance direct thrombus imaging. Ann Intern Med 2002, 136(2): 89-98. (Pubitemid 34073933)
6. Stein, P.D., Henry, J.W. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 1995, 108(4): 978-81.
7. Rasmusen, M.S., Wille-Jorgensen, P., Jorgensen, L.N. Postoperative fatal pulmonary embolism in a general surgical department. Am J Surg 1995, 169(2): 214-6.
8. Pellegrini, V.D., Donaldson, C.T., Farber, D.C., Lehman, E.B., Evarts, C.M. The Mark Coventry Award: Prevention of readmission for venous thromboembolism after total knee arthroplasty. Clin Orthop Relat Res 2006, 452(11): 21-7. (Pubitemid 44690637)
9. Douketis, J.D, Eikelboom, J.W., Quinlan, D.J., Willan, A.R., Crowther, M.A. Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: A meta-analysis of prospective studies investigating symptomatic outcomes. Arch Intern Med 2002, 162(13): 1465-71. (Pubitemid 34747479)
10. Seagroatt, V., Tan, H.S., Goldacre, M., Bulstrode, C., Nugent, I., Gill, L. Elective total hip replacement: incidence, emergency readmission rate, and postoperative mortality. Br Med J 1991, 303(6815): 1431-5.
11. Hirsch, J., O'Donell, M., Weitz J.I. New anticoagulants. Blood 2005, 105(2): 453-63. (Pubitemid 40070721)
12. Garcia, D., Libby, E., Crowther, M.A. The new oral anticoagulants. Blood 2010, 115(1): 15-20.
13. Turpie, A.G.G. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 2007, 27(6): 1238-47. (Pubitemid 46809411)
14. Mann, K.G., Brummel, K., Butenas, S. What is all that thrombin for? J Thromb Haemost 2003, 1(7): 1504-14.
15. Shimizu, T., Nishihira, J., Watanabe, H., Abe, R., Honda, A., Ishibashi, T., Shimizu, H. Macrophage migration inhibitory factor is induced by thrombin and factor Xa in endothelial cells. J Biol Chem 2004, 279(14): 13729-37. (Pubitemid 38468902)
16. Daiichi Sankyo launches LIXIANA® (edoxaban), a direct oral factor Xa inhibitor, in Japan for the prevention of venous thromboembolism after major orthopedic surgery [news release]. Daiichi Sankyo Co., Ltd., July 19, 2011.
17. Escolar, G., Díaz-Ricart, M. Edoxaban tosilate. Drugs Fut 2009, 34(11): 861-72.
18. th Annu Meet Am Soc Hematol (Dec 4-7, San Diego) 2004] 2004, 104(11, Part 1): Abst 1862.
19. Furugohri, T., Isobe, K., Honda, Y. et al. DU-176b, a potent and orally active factor Xa inhibitor: In vitro and in vivo pharmacological profiles. J Thromb Haemost 2008, 6(9): 1542-9.
20. nd Congr Int Soc Thromb Haemost (ISTH) (July 11-16, Boston) 2009, Abst PP-TH-406.
21. th Annu Meet Am Soc Hematol (Dec 4-7, San Diego) 2004] 2004, 104(11, Part 1): Abst 1852.
22. th Annu Meet Am Soc Hematol (Dec 4-7, San Diego) 2004] 2004, 104(11, Part 1): Abst 1851.
23. th Am Heart Assoc Sci Sess (Nov 12-15, Chicago) 2006] 2006, 114(18, Suppl. 2): Abst 632.
24. th Annu Meet Am Soc Hematol (Dec 10-13, Atlanta) 2005] 2005, 106(11): Abst 1878.
25. th Annu Meet Am Soc Hematol (Dec 10-13, Atlanta) 2005] 2005, 106(11): Abst 1874.
26. Ogata, K., Mendell-Harary, J., Tachibana, M., Masumoto, H., Oguma, T., Kojima, M., Kunitada, S. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010, 50(7): 743-53.
27. Mendell, J., Rohatagi, S., Rombout, F. et al. The oral factor XA inhibitor DU-176b: Population pharmacokinetic and pharmacodynamic models of coagulation biomarkers, efficacy, and safety. Clin Pharmacol Ther [Annu Meet Am Soc Clin Pharmacol Ther (ASCPT) (March 18-21, Washington, D.C.) 2009] 2009, 85(Suppl. 1): Abst OII-A-1.
28. th Annu Meet Am Coll Clin Pharmacol (ACCP) (Sept 13-15, San Antonio) 2009] 2009, 49(9): Abst 144.
29. th Annu Meet Am Coll Clin Pharmacol (ACCP) (Sept 13-15, San Antonio) 2009] 2009, 49(9): Abst 146.
30. th Annu Sci Sess Am Coll Cardiol (ACC) (April 3-5, New Orleans) 2011] 2011, 57(15): Abst 1075-118.
31. Ruff, C.T., Giugliano, R.P., Antman, E.M. et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010, 160(4): 635-41.
32. Comparative investigation of low molecular weight (LMW) heparin/edoxaban tosylate (DU-176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai- VTE Study; NCT00986154). ClinicalTrials.gov Web site, Accessed October 26, 2011.
33. Zafar, M.U., Vilahur, G., Vorchheimer, D. et al. DU-176b, a novel, orally active direct factor-Xa inhibitor, has anti-thrombotic properties in an ex-vivo model of thrombosis. Eur Heart J [World Congr Cardiol (Sept 2-6, Barcelona) 2006] 2006, 27(Abstract Suppl.): Abst P4570.
34. th Annu Sci Sess Am Coll Cardiol (ACC) (March 11-14, Atlanta) 2006] 2006, 47(4, Suppl. 1): Abst 908-161.
35. Zafar, M.U., Vorchheimer, D.A., Gaztanaga, J. et al. Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost 2007, 98(4): 883-8. (Pubitemid 47555083)
36. th Annu Meet Am Soc Hematol (Dec 6-9, San Francisco) 2008] 2008, 112(11): Abst 34.
37. Fuji, T., Wang, C.-J., Fujita, S. et al. Endoxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty: The STARS E-3 trial. Pathophysiol Haemos Thromb [21st International Congress on Thrombosis (July 6-9, Milan) 2010] 2009/2010, 37 (Suppl. 1): Abst OC297.
38. st Annu Meet Am Soc Hematol (Dec 5-8, New Orleans) 2009] 2009, 114(22): Abst 2098.
39. Raskob, G., Cohen, A., Eriksson, B. et al. Randomized double- blind multi-dose trial of the oral factor-Xa inhibitor DU- 176b versus LMW Heparin (Dalteparin) for prevention of venous thromboembolism after total hip replacement. Eur Heart J [ESC Congr (Aug 30-Sep 3, Munich) 2008] 2008, 29(Suppl.): Abst P3712.
40. nd Annu Meet Am Soc Hematol (Dec 4-7, Orlando) 2010] 2010, 116(21): Abst 3320.
41. Mendell, J., Basavapathruni, R., Swearingen, D., Draves, A., Zhang, D. The oral factor Xa inhibitor DU-176b: Thorough QT/QTc study to evaluate the effect of therapeutic and supratherapeutic exposure to DU-176b on QTc interval duration in healthy subjects. Clin Pharmacol Ther [Annu Meet Am Soc Clin Pharmacol Ther (ASCPT) (March 18-21, Washington, D.C.) 2009] 2009, 85(Suppl. 1): Abst PI-79.
42. th Congr Eur Assoc Clin Pharmacol Ther (EACPT) (July 12-15, Edinburgh) 2009] 2009, 105(Suppl. 1): Abst MP35.
43. th Annu Meet Am Coll Clin Pharmacol (ACCP) (Sept 13-15, San Antonio) 2009] 2009, 49(9): Abst 135.
44. nd Annu Meet Am Soc Hematol (Dec 4-7, Orlando) 2010] 2010, 116(21): 3321.
45. nd Congr Int Soc Thromb Haemost (ISTH) (July 11-16, Boston) 2009, Abst PP-WE-179.
46. th Annu Meet Am Soc Hematol (Dec 6-9, San Francisco) 2008] 2008, 112(11): Abst 3026.